CN111065386A - 减轻肺部感染的方法 - Google Patents

减轻肺部感染的方法 Download PDF

Info

Publication number
CN111065386A
CN111065386A CN201880040947.1A CN201880040947A CN111065386A CN 111065386 A CN111065386 A CN 111065386A CN 201880040947 A CN201880040947 A CN 201880040947A CN 111065386 A CN111065386 A CN 111065386A
Authority
CN
China
Prior art keywords
antibiotic
chelator
day
inhaled
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880040947.1A
Other languages
English (en)
Chinese (zh)
Inventor
B.克莱门茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rsprion Pharmaceuticals Pte Ltd
Original Assignee
Rsprion Pharmaceuticals Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902364A external-priority patent/AU2017902364A0/en
Application filed by Rsprion Pharmaceuticals Pte Ltd filed Critical Rsprion Pharmaceuticals Pte Ltd
Publication of CN111065386A publication Critical patent/CN111065386A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
CN201880040947.1A 2017-06-20 2018-06-20 减轻肺部感染的方法 Pending CN111065386A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2017902364A AU2017902364A0 (en) 2017-06-20 Method For Reducing Lung Infection
AU2017902364 2017-06-20
AU2018900765A AU2018900765A0 (en) 2018-03-08 Method for Reducing Lung Infection
AU2018900765 2018-03-08
PCT/AU2018/050610 WO2018232453A1 (en) 2017-06-20 2018-06-20 Method for reducing lung infection

Publications (1)

Publication Number Publication Date
CN111065386A true CN111065386A (zh) 2020-04-24

Family

ID=64735417

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880040947.1A Pending CN111065386A (zh) 2017-06-20 2018-06-20 减轻肺部感染的方法

Country Status (8)

Country Link
US (1) US11382884B2 (cg-RX-API-DMAC7.html)
EP (2) EP3641750A4 (cg-RX-API-DMAC7.html)
JP (2) JP7389653B2 (cg-RX-API-DMAC7.html)
CN (1) CN111065386A (cg-RX-API-DMAC7.html)
AU (3) AU2018286650B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019027255A2 (cg-RX-API-DMAC7.html)
CA (1) CA3067858A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018232453A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116173037A (zh) * 2023-04-14 2023-05-30 中国人民解放军总医院 咖啡因在预防和/或治疗急性高原病中的应用
CN116887829A (zh) * 2021-01-29 2023-10-13 美迪诺亚公司 治疗化学气体暴露的方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7376582B2 (ja) * 2018-10-22 2023-11-08 イーオーイー オレオ ゲーエムベーハー 成形体への圧縮を目的とした粉末材料用添加剤
US20250108004A1 (en) * 2023-09-29 2025-04-03 Sterilecare Inc. Aerosol delivery of edta compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080317799A1 (en) * 2007-05-02 2008-12-25 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US20160263151A1 (en) * 2015-03-11 2016-09-15 University Of Cincinnati Compositions and methods for treating bacterial infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
WO2011142677A1 (en) 2010-05-11 2011-11-17 Breathe Easy Ltd Methods and compositions for the treatment of lung disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080317799A1 (en) * 2007-05-02 2008-12-25 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US20160263151A1 (en) * 2015-03-11 2016-09-15 University Of Cincinnati Compositions and methods for treating bacterial infection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
E.M.TANAKA等: "n vitro antimicrobial sensitivity test with EDTA-Tris in strains of Pseudomonas aeruginosa", 《SCIELO网页公开》 *
NOBUMASA AOKI等: "Efficacy of Calcium-EDTA as an Inhibitor for Metallo- -Lactamase in a Mouse Model of Pseudomonas aeruginosa Pneumonia", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 *
邱妍川等: "治疗肺囊性纤维化的吸入药物研究进展", 《中国药房》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116887829A (zh) * 2021-01-29 2023-10-13 美迪诺亚公司 治疗化学气体暴露的方法
CN116173037A (zh) * 2023-04-14 2023-05-30 中国人民解放军总医院 咖啡因在预防和/或治疗急性高原病中的应用

Also Published As

Publication number Publication date
WO2018232453A1 (en) 2018-12-27
BR112019027255A2 (pt) 2020-07-14
US20200108033A1 (en) 2020-04-09
JP2024001036A (ja) 2024-01-09
EP3641750A1 (en) 2020-04-29
AU2023285900B2 (en) 2025-11-20
JP7642033B2 (ja) 2025-03-07
AU2018286650A1 (en) 2019-12-05
US11382884B2 (en) 2022-07-12
AU2018286650B2 (en) 2023-09-21
JP7389653B2 (ja) 2023-11-30
EP4759301A3 (en) 2026-08-19
AU2023285900A1 (en) 2024-01-18
JP2020524172A (ja) 2020-08-13
EP3641750A4 (en) 2021-03-24
CA3067858A1 (en) 2018-12-27
EP4759301A2 (en) 2026-06-17
AU2025256218A1 (en) 2025-11-13

Similar Documents

Publication Publication Date Title
JP7642033B2 (ja) 肺感染症を低減させる方法
JP4646489B2 (ja) 肺細菌感染症の治療及び予防のための吸入可能なアズトレオナム
US9968555B2 (en) Liposomal formulations that form drug nanocrystals after freeze-thaw
JP4745340B2 (ja) 細菌性呼吸器感染症を治療するためのエーロゾル化されたホスホマイシン/アミノグリコシド組合せ
US20160263151A1 (en) Compositions and methods for treating bacterial infection
WO2007124382A2 (en) Inhaled imipenem
US20240173343A9 (en) Aminoglycoside potentiation for treatment of pulmonary bacterial infection
JP2025098035A (ja) 肺炎症を低減させる方法
US20230226099A1 (en) Inhalable formulation
BR122025016291A2 (pt) Uso do agente quelante ácido etilenodiamino tetra-acético (edta) na fabricação de uma formulação inalável, formulação inalável e kit para tratar ou prevenir inflamação no pulmão

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination